

## **ASX Announcement**

### **Distribution Schedule and Top 20**

---

**Sydney, Australia, 3 October 2023:** Imugene Limited (ASX:IMU) (Imugene, or the Company) is pleased to provide the Distribution Schedule and Top 20 for the options quoted today in accordance with ASX Listing Rule 3.10.5.

*Release approved by the Company Secretary on behalf of the Board.*

For more information please contact:

**Leslie Chong**  
**Managing Director and Chief Executive Officer**  
info@imugene.com

**Investor Enquiries**  
shareholderenquiries@imugene.com

**Media Enquiries**  
Matt Wright  
matt@nwrcommunications.com.au

Follow us on Twitter @TeamImugene  
Like us on Facebook @Imugene  
Connect with us on LinkedIn @Imugene Limited  
View us on YouTube @Imugene Limited





## About Imugene (ASX:IMU)

Imugene is a clinical stage immuno-oncology company developing a range of new and novel immunotherapies that seek to activate the immune system of cancer patients to treat and eradicate tumours. Our unique platform technologies seek to harness the body's immune system against tumours, potentially achieving a similar or greater effect than synthetically manufactured monoclonal antibody and other immunotherapies. Our pipeline includes an off-the-shelf (allogeneic) cell therapy CAR T drug azer-cel (azercabtagene zapreleucel) which targets CD19 to treat blood cancers. Our pipeline also includes multiple immunotherapy B-cell vaccine candidates and an oncolytic virotherapy (CF33) aimed at treating a variety of cancers in combination with standard of care drugs and emerging immunotherapies such as CAR T's for solid tumours. We are supported by a leading team of international cancer experts with extensive experience in developing new cancer therapies with many approved for sale and marketing for global markets.

Our vision is to help transform and improve the treatment of cancer and the lives of the millions of patients who need effective treatments. This vision is backed by a growing body of clinical evidence and peer-reviewed research. Imugene is well funded and resourced, to deliver on its commercial and clinical milestones. Together with leading specialists and medical professionals, we believe Imugene's immuno-oncology therapies will become foundation treatments for cancer. Our goal is to ensure that Imugene and its shareholders are at the forefront of this rapidly growing global market.



# Holdings Range Report

Imugene Limited

Security Class(es): IMUOP38 - UNL OPT @ \$0.118 EXP 31/08/2026

 As at Date: 03-Oct-2023

Holding Ranges	Holders	Total Units	% Issued Share Capital
above 0 up to and including 1,000	0	0	0.00%
above 1,000 up to and including 5,000	0	0	0.00%
above 5,000 up to and including 10,000	0	0	0.00%
above 10,000 up to and including 100,000	734	37,268,316	5.02%
above 100,000	683	704,667,432	94.98%
<b>TOTALS</b>	<b>1,417</b>	<b>741,935,748</b>	<b>100.00%</b>

 Report generated on 03-Oct-2023 at 11:20 AM



# Top Holders Grouped Report

## Imugene Limited


Security Class(es): IMUOP38 - UNL OPT @ \$0.118 EXP 31/08/2026

Display Top: 20


 As at Date: 03-Oct-2023

Position	Holder Name	Holding	% IC
1	CITICORP NOMINEES PTY LIMITED	128,355,218	17.30%
2	MERRILL LYNCH (AUSTRALIA) NOMINEES PTY LIMITED	121,428,571	16.37%
3	BILGOLA NOMINEES PTY LIMITED	35,714,286	4.81%
4	BNP PARIBAS NOMINEES PTY LTD <IB AU NOMS RETAILCLIENT DRP>	24,455,275	3.30%
5	HSBC CUSTODY NOMINEES (AUSTRALIA) LIMITED - A/C 2	24,166,666	3.26%
6	HSBC CUSTODY NOMINEES (AUSTRALIA) LIMITED-GSCO ECA	23,809,524	3.21%
7	J P MORGAN NOMINEES AUSTRALIA PTY LIMITED	23,224,452	3.13%
8	NATIONAL NOMINEES LIMITED	19,185,787	2.59%
9	HSBC CUSTODY NOMINEES (AUSTRALIA) LIMITED	13,818,443	1.86%
10	MORGAN STANLEY AUSTRALIA SECURITIES (NOMINEE) PTY LIMITED <NO 1 ACCOUNT>	11,904,762	1.60%
11	UBS NOMINEES PTY LTD	7,785,457	1.05%
12	DRM TECHNOLOGIES PTY LTD	4,866,698	0.66%
13	BNP PARIBAS NOMINEES PTY LTD HUB24 CUSTODIAL SERV LTD <DRP A/C>	4,294,636	0.58%



Position	Holder Name	Holding	% IC
14	ABN AMRO CLEARING SYDNEY NOMINEES PTY LTD <CUSTODIAN A/C>	3,940,785	0.53%
15	JAMAPHARMA CONSULTING LLC	3,666,667	0.49%
16	NETWEALTH INVESTMENTS LIMITED <WRAP SERVICES A/C>	3,454,893	0.47%
17	BLJ TECHNOLOGIES PTY LTD	2,920,019	0.39%
18	 <b>Mi Ok Chong</b>	2,916,666	0.39%
19	MS DEBORAH ANNE COLEMAN	2,380,952	0.32%
20	BNP PARIBAS NOMS PTY LTD <DRP>	2,241,137	0.30%
<b>TOTALS</b>		<b>464,530,894</b>	<b>62.61%</b>
<b>Total Issued Capital</b>		<b>741,935,748</b>	<b>100.00%</b>

 Holding is aggregated over a shareholder group

 Report generated on 03-Oct-2023 at 11:20 AM